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Amyloid-Beta Solubility in the Treatment of Alzheimer’s
Disease
M. Paul Murphy, Ph.D.
There is general agreement that Alzheimer’s dis
ease will become a crisis by the middle of the
century. The Alzheimer’s Association estimates
that 5 million Americans currently have Alzhei
mer’s disease and that their loved ones devote
nearly 18 billion hours annually toward their
care. If Alzheimer’s disease remains unchecked,
these numbers are projected to more than triple
by 2050, and the economic burden will exceed
$1 trillion per year. The quest to find an effective
therapy has been urgent. For nearly two decades,
since the first report of a successful amyloidbeta (Aβ) immunotherapy in mice,1 this goal has
seemed tantalizingly close.
In this issue of the Journal, Honig et al.2 report
the results of the EXPEDITION3 trial of solanezu
mab, a humanized monoclonal antibody that has
been designed to clear soluble Aβ from the brain.
This trial was a follow-up to two earlier trials
of solanezumab,3 in which secondary analyses
showed a modest effect in slowing cognitive de
cline. Unfortunately, the EXPEDITION3 trial did
not replicate this earlier finding and instead be
comes another disappointment for amyloid im
munotherapy. Although several trials of other
immunotherapies are ongoing, this outcome raises
several broader issues.
The EXPEDITION3 trial included only patients
with mild cases of Alzheimer’s disease who had
some evidence of amyloid disease, as determined
either by means of florbetapir (an 18fluorinelabeled reagent that binds to Aβ) positronemission tomography or by means of cerebro
spinal fluid measurements of Aβ1-42. Although
this effort does not differ substantially from
others that have sought to intervene at an early
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stage of disease, which might be more amenable
to treatment, it brings up the question, “How
early is early enough?” Researchers have known
for some time that the mouse models that we
rely on to provide preclinical data are much
closer to humans with prodromal Alzheimer’s
disease than to persons who have the earliest
symptomatic stages of the disease.4 A reasonable
argument has been made that antiamyloid thera
pies may yet work as a primary preventive strat
egy.5 For example, persons who have a strong
family history of Alzheimer’s disease or who
have a dominantly inherited amyloid mutation
are motivated participants in clinical trials for
the prevention of Alzheimer’s disease. Although
two ongoing trials — DIAN-TU (Dominantly
Inherited Alzheimer Network Trial, involving
persons with dominantly inherited mutations;
ClinicalTrials.gov number, NCT01760005) and
A4 (Anti-Amyloid Treatment in Asymptomatic
Alzheimer’s Trial, involving persons at risk for
Alzheimer’s disease; NCT02008357) — will par
tially address the question of amyloid removal in
disease prevention, we are still several years
from knowing their results.
The trial conducted by Honig et al. could
point to an alternative possibility, one that is
potentially more promising (or at least intrigu
ing). The authors point out that solanezumab
was highly effective at targeting soluble Aβ. Al
though it is possible that the magnitude of re
duction in soluble Aβ was simply insufficient to
create a measurable clinical benefit, recent re
sults from an early trial of aducanumab could
indicate that the ability of an antiamyloid therapy
to clear insoluble Aβ is an important factor in

nejm.org

January 25, 2018

The New England Journal of Medicine
Downloaded from nejm.org at UNIV OF KENTUCKY on November 13, 2018. For personal use only. No other uses without permission.
Copyright © 2018 Massachusetts Medical Society. All rights reserved.

391

The

n e w e ng l a n d j o u r na l

the success of treatment.6 If clearing previously
deposited amyloid from the brain is more impor
tant than preventing its production, this could
also at least partially explain the lack of success
with other strategies such as beta-secretase in
hibitors that have, after initial promise,7 proved
disappointing.8 It is also possible that some
other characteristic of aducanumab, such as its
relatively higher penetration in the brain, as com
pared with solanezumab, explains the difference.
A final determination rests on the outcome
of ongoing studies of aducanumab (ENGAGE
[NCT02477800] and EMERGE [NCT02484547]),
which expand the scope to an international trial
(at different sites).
Although it may not quite be time to give up
on Aβ immunotherapy for treating Alzheimer’s
disease, it would be foolish to ignore the contin
ued failures of antiamyloid approaches. In spite
of the mountain of evidence supporting the
primacy of Aβ in Alzheimer’s disease, many re
searchers are coming to the realization that our
preclinical models of the disease may be miss
ing the mark. Even if there is some future suc
cess in a primary prevention trial, there is still
little headway being made in improving the
treatment of Alzheimer’s disease. There is some
hope that a combination of therapeutic approach
es might help, since there is evidence that the
different pathologic aspects of Alzheimer’s dis
ease are interactive.9 Whether a multifaceted
strategy or something entirely unforeseen is the
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answer, the field is clearly in need of innovative
ideas. We may very well be nearing the end of
the amyloid-hypothesis rope, at which point one
or two more failures will cause us to loosen our
grip and let go.
Disclosure forms provided by the author are available with the
full text of this editorial at NEJM.org.
From the Department of Molecular and Cellular Biochemistry
and the Sanders-Brown Center on Aging, University of Kentucky Medical Center, Lexington.
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Progress in the Treatment of Hodgkin’s Lymphoma
Dan L. Longo, M.D., and Vincent T. DeVita, Jr., M.D.
Although there has been considerable research
activity in the treatment of Hodgkin’s lymphoma
since advanced stages of the disease became
curable with combination chemotherapy in the
1960s, the most significant advances have in
volved the maintenance of a particular level of
antitumor efficacy while acute and late toxic side
effects and their attendant mortality are reduced.
These advances include the preservation of high
response rates at reduced levels of toxicity with
the current standard regimen of doxorubicin,
bleomycin, vinblastine, and dacarbazine (ABVD);
the demonstration that various forms of radia
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tion therapy were associated with unacceptably
high levels of long-term toxicity; the application
of high-dose salvage chemotherapy; and the tailor
ing of treatment to the evidence of response re
vealed on midterm positron-emission tomogra
phy (PET). Little progress has been made in
improving overall survival.
Two notable exceptions to this general lack of
progress in the development of newer approach
es to treatment are the application of the CD30
immunotoxin brentuximab vedotin1 and the pro
grammed death 1–inhibitor nivolumab2 to the
treatment of patients with Hodgkin’s lymphoma
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